12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GFT505: Phase IIb ongoing

Genfit said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international, pivotal Phase IIb GFT505-212-7 trial of once-daily oral GFT505 for 12 months. The DSMB concluded that >6 months of treatment with 80 mg GFT505...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >